Short term & long term clinical study using Pureis® CBD

Short term & long term clinical study using Pureis® CBD

As a responsible pharmaceutical company, we have invested in safety clinical studies to prove the safety of Pureis for human use. 

The results of our short term and longer term clinical studies demonstrated that our Pureis CBD is safe for consumer consumption.

In addition, when testing any product, it is important that the product does not interfere with the body’s natural ability to make new cells. We conducted a series of tests to demonstrate that Pureis CBD does not have any mutagenic effects – the results confirmed that Pureis CBD has no evidence of mutagenicity.

We at Pureis have created a safe range of 10mg and 20mg daily doses of CBD products in various forms.

We have worked with a Clinical Research Organisation (CRO) which is widely known and highly accredited. Our CRO applied the most stringent guidelines in compliance with Organisation for Economic Cooperation and Development (OECD) principles and Good Laboratory Practice (GLP) in conducting our studies.

These clinical studies on our Pureis CBD were conducted in accordance with the European and UK Food Safety Authority. The results of these studies demonstrated that our Pureis CBD products have being rigorously quality tested and proven safe for consumer use. 

CBD is also permitted by WADA (World Anti-Doping Agency).

Some of the studies we have completed on Pureis CBD are described below. It is important to highlight these studies are applicable to Pureis CBD due to its carefully designed purity and specification. These studies are not representative of other CBD products in general, either from a natural grown or synthetically derived CBD compound. Many regulatory agencies, such as the European and UK Food Safety Authority, require that a series of studies are undertaken in order to demonstrate that products are suitable for consumer use.


Short term clinical study using Pureis CBD

The objective of this study was to determine the potential toxicity of Pureis CBD, when given orally to the subjects for a short term. The purpose of this study was to determine suitable doses for a subsequent longer study, as detailed below. 


Longer term clinical study using Pureis CBD

This longer term study provides information on the possible health hazards likely to arise from repeated exposure over a prolonged period of time. 

During this study, there was no sign of adverse events. Various parameters were assessed during this study such as, but not limited to: clinical observations, mobility, reaction sensation, body temperature, ophthalmology (conditions relating to the eye), haematology (blood analysis), clinical chemistry (analysis of bodily fluids), organ and tissue examination, histology (microscopic structure of tissues) and sperm evaluation.

 

Graph 1 – Summary of Body Weights in study



Final body weights and food consumption were comparable between the subjects given Pureis CBD, as observed in Graph 1. 

The yellow “control” line represents the subjects that did not take CBD during the trial.

The body weight of the subjects that took 10mg, 25mg and 50mg of CBD had the same body weight as those that did not take CBD. This shows that Pureis CBD was well tolerated and caused no toxic effect to any part of the body and is safe.


Conclusion of Pureis CBD studies

The results of our short term and longer term clinical studies demonstrated that our Pureis CBD is safe for consumer consumption.

In addition, when testing any product, it is important that the product does not interfere with the body’s natural ability to make new cells. We conducted a series of tests to demonstrate that Pureis CBD does not have any mutagenic effects – the results confirmed that Pureis CBD has no evidence of mutagenicity.

We at Pureis have created a safe range of 10mg and 20mg daily doses of CBD products in various forms.

Sign Up to Stay Up to Date!

The first CBD food supplement clinically proven to be safe

Sign up to get 10% off your first order!

By clicking SUBMIT you agree to receiving future communications from Pureis. Read our full privacy policy.

newsletter modal